• What is FGFR2?
  • FGFR2 in Breast Cancer
  • Clinical Trials

FGFR2

The fibroblast growth factor receptor 2 gene (FGFR2) encodes one member of the FGFR tyrosine kinase (TK) family, which includes four kinases: FGFR1, 2, 3, and 4 (Figure 1). FGFR TKs play crucial roles in development and have been shown in cancers to be deregulated by amplification, point mutation, or translocation (Turner and Grose 2010). Amplification or activation of FGFR2 has been reported in breast cancer and gastric cancer (Jain and Turner 2012). FGFR2 mutations have been observed in endometrial cancer and breast cancer (Dutt et al. 2008; Jain and Turner 2012; Reintjes et al. 2013).

FGFR2 

Figure 1. Schematic of FGFR signaling pathway. Growth factor binding to FGFR results in activation of the MAPK signaling pathway (RAS-RAF-MEK-ERK). The letter "K" within the schema denotes the tyrosine kinase domain.

Related Pathways

Contributors: Nicholas Turner, M.D., Ph.D.

Suggested Citation: Turner, N. 2015. FGFR2. My Cancer Genome https://www.padiracinnovation.org/content/disease/breast-cancer/fgfr2/?tab=0 (Updated December 7).

Last Updated: December 7, 2015

FGFR2 in Breast Cancer

The chromosomal region at 10q26 containing the FGFR2 gene locus is amplified in about 1-2% of breast cancer patients (Jain and Turner 2012; Heiskenen et al. 2001; TCGA-cBio). Jain and Turner (2012) noted that FGFR2 amplification is uncommon in breast cancer, but occurs a little more frequently in triple-negative breast cancer. Fluorescence in situ hybridization (FISH) is typically used to determine whether amplification is present. Preclinical data suggest that cancer cells with amplified FGFR2 may be sensitive to FGFR inhibitors (Bai et al. 2010; Jain and Turner 2012). Somatic FGFR2 mutations have also been observed in breast cancer (Reintjes et al. 2013).

Gene Invasive Breast Cancer Hormone Receptor Positive (ER+ and/or PR+) Invasive Breast Cancer HER2 Positive Invasive Breast Cancer Triple-Negative Invasive Breast Cancer
FGFR2 1-2% (Jain and Turner 2012; Heiskenen et al. 2001; TCGA-cBio) 4.8% (TCGA-cBio) 1% (TCGA-cBio) 2-4% (Jain and Turner 2012; Turner et al. 2010​; TCGA-cBio)

a Data from Heiskenen et al. (2001) were measured using microarray comparative genomic hybridization (aCGH). Data from TCGA-cBio were measured using next-generation sequencing (NGS). Data from Turner et al. (2010) were measured using aCGH and gene expression analysis.

Contributors: Nicholas Turner, M.D., Ph.D.

Suggested Citation: Turner, N. 2013. FGFR2 in Breast Cancer. My Cancer Genome https://www.padiracinnovation.org/content/disease/breast-cancer/fgfr2/ (Updated October 1).

Last Updated: October 1, 2013

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.padiracinnovation.org to check it out!

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.